574 related articles for article (PubMed ID: 34370181)
1. Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer.
Vázquez SM; Endepols H; Fischer T; Tawadros SG; Hohberg M; Zimmermanns B; Dietlein F; Neumaier B; Drzezga A; Dietlein M; Schomäcker K
Mol Imaging Biol; 2022 Feb; 24(1):115-125. PubMed ID: 34370181
[TBL] [Abstract][Full Text] [Related]
2. An
Dietlein F; Kobe C; Vázquez SM; Fischer T; Endepols H; Hohberg M; Reifegerst M; Neumaier B; Schomäcker K; Drzezga AE; Dietlein M
J Nucl Med; 2022 Apr; 63(4):573-583. PubMed ID: 34326129
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Radiolabeling of PSMA-617 with
Imura R; Ozeki AN; Shida N; Kobayashi M; Ida H; Wada Y; Akimitsu N; Kumakura Y
Nucl Med Biol; 2022; 106-107():21-28. PubMed ID: 34998216
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers.
Xu J; Cai F; Luo Z; Fan W; Dai J; Cui J; Li S; Geng C; Zheng Q; Wang Z; Tang X
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2618-2633. PubMed ID: 35347438
[TBL] [Abstract][Full Text] [Related]
6. Detection efficacy of [
Rosar F; Khreish F; Marlowe RJ; Schaefer-Schuler A; Burgard C; Maus S; Petto S; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2899-2909. PubMed ID: 37148297
[TBL] [Abstract][Full Text] [Related]
7. [
Rosar F; Burgard C; Larsen E; Khreish F; Marlowe RJ; Schaefer-Schuler A; Maus S; Petto S; Bartholomä M; Ezziddin S
Cancer Imaging; 2024 Feb; 24(1):27. PubMed ID: 38389092
[TBL] [Abstract][Full Text] [Related]
8. [
Rosar F; Schaefer-Schuler A; Bartholomä M; Maus S; Petto S; Burgard C; Privé BM; Franssen GM; Derks YHW; Nagarajah J; Khreish F; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4736-4747. PubMed ID: 35930033
[TBL] [Abstract][Full Text] [Related]
9. In Vitro and In Vivo Characterization of an
Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
[TBL] [Abstract][Full Text] [Related]
10. A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer.
Dam JH; Olsen BB; Baun C; Høilund-Carlsen PF; Thisgaard H
Mol Imaging Biol; 2017 Dec; 19(6):915-922. PubMed ID: 28924629
[TBL] [Abstract][Full Text] [Related]
11. Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3.
Korsen JA; Kalidindi TM; Khitrov S; Samuels ZV; Chakraborty G; Gutierrez JA; Poirier JT; Rudin CM; Chen Y; Morris MJ; Pillarsetty N; Lewis JS
J Nucl Med; 2022 Sep; 63(9):1401-1407. PubMed ID: 35058323
[TBL] [Abstract][Full Text] [Related]
12. Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET.
Ruggiero A; Holland JP; Hudolin T; Shenker L; Koulova A; Bander NH; Lewis JS; Grimm J
J Nucl Med; 2011 Oct; 52(10):1608-15. PubMed ID: 21908391
[TBL] [Abstract][Full Text] [Related]
13.
Privé BM; Derks YHW; Rosar F; Franssen GM; Peters SMB; Khreish F; Bartholomä M; Maus S; Gotthardt M; Laverman P; Konijnenberg MW; Ezziddin S; Nagarajah J; Heskamp S
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2064-2076. PubMed ID: 34932154
[TBL] [Abstract][Full Text] [Related]
14. Effects of Linker Modification on Tumor-to-Kidney Contrast of
Kuo HT; Pan J; Zhang Z; Lau J; Merkens H; Zhang C; Colpo N; Lin KS; Bénard F
Mol Pharm; 2018 Aug; 15(8):3502-3511. PubMed ID: 29920108
[No Abstract] [Full Text] [Related]
15. Clinical Translation and First In-Human Use of [
Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
[TBL] [Abstract][Full Text] [Related]
16.
Wu W; Yu F; Zhang P; Bu T; Fu J; Ai S; You Q; Shi L; Shao G; Wang F; Hodolic M; Guo H
J Nucl Med; 2022 Sep; 63(9):1394-1400. PubMed ID: 35177423
[TBL] [Abstract][Full Text] [Related]
17. Consecutive Prostate-Specific Membrane Antigen (PSMA) and Antigen Receptor (AR) PET Imaging Shows Positive Correlation with AR and PSMA Protein Expression in Primary Hormone-Naïve Prostate Cancer.
Al Jalali V; Wasinger G; Rasul S; Grubmüller B; Wulkersdorfer B; Balber T; Mitterhauser M; Simon J; Hacker M; Shariat S; Egger G; Zeitlinger M
J Nucl Med; 2023 Jun; 64(6):863-868. PubMed ID: 36657982
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo comparative study of a novel
Chen H; Cai P; Feng Y; Sun Z; Wang Y; Chen Y; Zhang W; Liu N; Zhou Z
Sci Rep; 2021 Sep; 11(1):19122. PubMed ID: 34580375
[No Abstract] [Full Text] [Related]
19. An
Dietlein F; Hohberg M; Kobe C; Zlatopolskiy BD; Krapf P; Endepols H; Täger P; Hammes J; Heidenreich A; Neumaier B; Drzezga A; Dietlein M
J Nucl Med; 2020 Feb; 61(2):202-209. PubMed ID: 31324713
[TBL] [Abstract][Full Text] [Related]
20. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.
Holland JP; Divilov V; Bander NH; Smith-Jones PM; Larson SM; Lewis JS
J Nucl Med; 2010 Aug; 51(8):1293-300. PubMed ID: 20660376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]